ID   FOXM1_HUMAN             Reviewed;         763 AA.
AC   Q08050; O43258; O43259; O43260; Q4ZGG7; Q9BRL2;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 3.
DT   07-APR-2021, entry version 214.
DE   RecName: Full=Forkhead box protein M1;
DE   AltName: Full=Forkhead-related protein FKHL16;
DE   AltName: Full=Hepatocyte nuclear factor 3 forkhead homolog 11;
DE            Short=HFH-11;
DE            Short=HNF-3/fork-head homolog 11;
DE   AltName: Full=M-phase phosphoprotein 2;
DE   AltName: Full=MPM-2 reactive phosphoprotein 2;
DE   AltName: Full=Transcription factor Trident;
DE   AltName: Full=Winged-helix factor from INS-1 cells;
GN   Name=FOXM1; Synonyms=FKHL16, HFH11, MPP2, WIN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 4).
RC   TISSUE=Colon carcinoma;
RX   PubMed=9032290; DOI=10.1128/mcb.17.3.1626;
RA   Ye H., Kelly T.F., Samadani U., Lim L., Rubio S., Overdier D.G.,
RA   Roebuck K.A., Costa R.H.;
RT   "Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in
RT   proliferating epithelial and mesenchymal cells of embryonic and adult
RT   tissues.";
RL   Mol. Cell. Biol. 17:1626-1641(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Pancreatic carcinoma, and Testis;
RX   PubMed=9242644; DOI=10.1074/jbc.272.32.19827;
RA   Yao K.-M., Sha M., Lu Z., Wong G.G.;
RT   "Molecular analysis of a novel winged helix protein, WIN. Expression
RT   pattern, DNA binding property, and alternative splicing within the DNA
RT   binding domain.";
RL   J. Biol. Chem. 272:19827-19836(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-402; LEU-450; PRO-643;
RP   ARG-669 AND LEU-673.
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   PRO-643.
RC   TISSUE=Lung, Ovary, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 543-763.
RC   TISSUE=Lymphoblast;
RX   PubMed=8290587; DOI=10.1073/pnas.91.2.714;
RA   Westendorf J.M., Rao P.N., Gerace L.;
RT   "Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2
RT   monoclonal antibody and determination of the phosphorylated epitope.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:714-718(1994).
RN   [6]
RP   FUNCTION IN DNA REPAIR, AND PHOSPHORYLATION AT SER-376 BY CHEK2.
RX   PubMed=17101782; DOI=10.1128/mcb.01068-06;
RA   Tan Y., Raychaudhuri P., Costa R.H.;
RT   "Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate
RT   expression of DNA repair genes.";
RL   Mol. Cell. Biol. 27:1007-1016(2007).
RN   [7]
RP   FUNCTION, PHOSPHORYLATION AT THR-611; SER-693; SER-730 AND SER-739, AND
RP   MUTAGENESIS OF THR-611; SER-693; SER-730 AND SER-739.
RX   PubMed=19160488; DOI=10.1038/ncb1767;
RA   Fu Z., Malureanu L., Huang J., Wang W., Li H., van Deursen J.M.,
RA   Tindall D.J., Chen J.;
RT   "Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional
RT   programme required for mitotic progression.";
RL   Nat. Cell Biol. 10:1076-1082(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-331; THR-620 AND THR-627, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-730 AND SER-739, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-522, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-356 AND LYS-440, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [12]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-201; LYS-356 AND LYS-422, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [13]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-201 AND LYS-356, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [14]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-163; LYS-201; LYS-325; LYS-356;
RP   LYS-422 AND LYS-440, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.21 ANGSTROMS) OF 222-360 IN COMPLEX WITH PROMOTER
RP   DNA, AND FUNCTION.
RX   PubMed=20360045; DOI=10.1093/nar/gkq194;
RA   Littler D.R., Alvarez-Fernandez M., Stein A., Hibbert R.G., Heidebrecht T.,
RA   Aloy P., Medema R.H., Perrakis A.;
RT   "Structure of the FoxM1 DNA-recognition domain bound to a promoter
RT   sequence.";
RL   Nucleic Acids Res. 38:4527-4538(2010).
CC   -!- FUNCTION: Transcriptional factor regulating the expression of cell
CC       cycle genes essential for DNA replication and mitosis. Plays a role in
CC       the control of cell proliferation. Plays also a role in DNA breaks
CC       repair participating in the DNA damage checkpoint response.
CC       {ECO:0000269|PubMed:17101782, ECO:0000269|PubMed:19160488,
CC       ECO:0000269|PubMed:20360045}.
CC   -!- INTERACTION:
CC       Q08050; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-866480, EBI-11524452;
CC       Q08050; Q8N9N5-7: BANP; NbExp=3; IntAct=EBI-866480, EBI-16429296;
CC       Q08050; P24864: CCNE1; NbExp=2; IntAct=EBI-866480, EBI-519526;
CC       Q08050; P35222: CTNNB1; NbExp=16; IntAct=EBI-866480, EBI-491549;
CC       Q08050; P14868: DARS1; NbExp=2; IntAct=EBI-866480, EBI-358730;
CC       Q08050; O43524: FOXO3; NbExp=2; IntAct=EBI-866480, EBI-1644164;
CC       Q08050; Q13416: ORC2; NbExp=2; IntAct=EBI-866480, EBI-374957;
CC       Q08050; O00541: PES1; NbExp=2; IntAct=EBI-866480, EBI-1053271;
CC       Q08050; O75152: ZC3H11A; NbExp=2; IntAct=EBI-866480, EBI-748480;
CC       Q08050-1; Q00534: CDK6; NbExp=2; IntAct=EBI-866499, EBI-295663;
CC       Q08050-1; P03129: E7; Xeno; NbExp=3; IntAct=EBI-866499, EBI-866453;
CC       Q08050-2; B4DE54: BANP; NbExp=3; IntAct=EBI-5237510, EBI-16429313;
CC       Q08050-2; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-5237510, EBI-11524452;
CC       Q08050-2; Q8N9N5-7: BANP; NbExp=3; IntAct=EBI-5237510, EBI-16429296;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Isoform 1 and isoform 2 appear to be the only activators of
CC         gene transcription. Isoform 3, found in rat, does not seem to exist
CC         in human.;
CC       Name=1; Synonyms=FoxM1C, FOXM1-c;
CC         IsoId=Q08050-1; Sequence=Displayed;
CC       Name=2; Synonyms=FoxM1B, FOXM1-b;
CC         IsoId=Q08050-2; Sequence=VSP_001547;
CC       Name=4; Synonyms=FoxM1A, FOXM1-a;
CC         IsoId=Q08050-3; Sequence=VSP_001548;
CC   -!- TISSUE SPECIFICITY: Expressed in thymus, testis, small intestine, colon
CC       followed by ovary. Appears to be expressed only in adult organs
CC       containing proliferating/cycling cells or in response to growth
CC       factors. Also expressed in epithelial cell lines derived from tumors.
CC       Not expressed in resting cells. Isoform 2 is highly expressed in
CC       testis.
CC   -!- DEVELOPMENTAL STAGE: Embryonic expression pattern: liver, lung,
CC       intestine, kidney, urinary tract; adult expression pattern: intestine,
CC       colon, testis and thymus.
CC   -!- INDUCTION: Induced during liver regeneration and oxidative stress.
CC   -!- DOMAIN: Within the protein there is a domain which acts as a
CC       transcriptional activator. Insertion of a splicing sequence within it
CC       inactivates this transcriptional activity, as it is the case for
CC       isoform 4.
CC   -!- PTM: Phosphorylated in M (mitotic) phase. Phosphorylation by the
CC       checkpoint kinase CHEK2 in response to DNA damage increases the FOXM1
CC       protein stability probably stimulating the transcription of genes
CC       involved in DNA repair. Phosphorylated by CDK1 in late S and G2 phases,
CC       creating docking sites for the POLO box domains of PLK1. Subsequently,
CC       PLK1 binds and phosphorylates FOXM1, leading to activation of
CC       transcriptional activity and subsequent enhanced expression of key
CC       mitotic regulators. {ECO:0000269|PubMed:17101782,
CC       ECO:0000269|PubMed:19160488}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FOXM1ID40631ch12p13.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/foxm1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U74612; AAC51128.1; -; mRNA.
DR   EMBL; U74613; AAC51129.1; -; mRNA.
DR   EMBL; U83113; AAC63595.1; -; mRNA.
DR   EMBL; DQ022289; AAY26401.1; -; Genomic_DNA.
DR   EMBL; BC006192; AAH06192.1; -; mRNA.
DR   EMBL; BC006529; AAH06529.1; -; mRNA.
DR   EMBL; BC012863; AAH12863.1; -; mRNA.
DR   EMBL; L16783; AAC37541.1; -; mRNA.
DR   CCDS; CCDS8515.1; -. [Q08050-1]
DR   CCDS; CCDS8516.1; -. [Q08050-3]
DR   CCDS; CCDS8517.1; -. [Q08050-2]
DR   PIR; B36881; B36881.
DR   RefSeq; NP_001230017.1; NM_001243088.1.
DR   RefSeq; NP_001230018.1; NM_001243089.1.
DR   RefSeq; NP_068772.2; NM_021953.3. [Q08050-1]
DR   RefSeq; NP_973731.1; NM_202002.2. [Q08050-3]
DR   RefSeq; NP_973732.1; NM_202003.2. [Q08050-2]
DR   PDB; 3G73; X-ray; 2.21 A; A/B=222-360.
DR   PDBsum; 3G73; -.
DR   SMR; Q08050; -.
DR   BioGRID; 108594; 96.
DR   CORUM; Q08050; -.
DR   DIP; DIP-36754N; -.
DR   IntAct; Q08050; 61.
DR   MINT; Q08050; -.
DR   STRING; 9606.ENSP00000342307; -.
DR   iPTMnet; Q08050; -.
DR   PhosphoSitePlus; Q08050; -.
DR   BioMuta; FOXM1; -.
DR   DMDM; 12644391; -.
DR   CPTAC; CPTAC-1242; -.
DR   jPOST; Q08050; -.
DR   MassIVE; Q08050; -.
DR   PaxDb; Q08050; -.
DR   PeptideAtlas; Q08050; -.
DR   PRIDE; Q08050; -.
DR   ProteomicsDB; 58567; -. [Q08050-1]
DR   ProteomicsDB; 58568; -. [Q08050-2]
DR   ProteomicsDB; 58569; -. [Q08050-3]
DR   Antibodypedia; 4507; 470 antibodies.
DR   DNASU; 2305; -.
DR   Ensembl; ENST00000342628; ENSP00000342307; ENSG00000111206. [Q08050-3]
DR   Ensembl; ENST00000359843; ENSP00000352901; ENSG00000111206. [Q08050-1]
DR   Ensembl; ENST00000361953; ENSP00000354492; ENSG00000111206. [Q08050-2]
DR   GeneID; 2305; -.
DR   KEGG; hsa:2305; -.
DR   UCSC; uc001qle.4; human. [Q08050-1]
DR   CTD; 2305; -.
DR   DisGeNET; 2305; -.
DR   GeneCards; FOXM1; -.
DR   HGNC; HGNC:3818; FOXM1.
DR   HPA; ENSG00000111206; Tissue enhanced (lymphoid tissue, testis).
DR   MIM; 602341; gene.
DR   neXtProt; NX_Q08050; -.
DR   OpenTargets; ENSG00000111206; -.
DR   PharmGKB; PA28236; -.
DR   VEuPathDB; HostDB:ENSG00000111206.12; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   GeneTree; ENSGT00940000158804; -.
DR   HOGENOM; CLU_027498_0_0_1; -.
DR   InParanoid; Q08050; -.
DR   OMA; EELSHSW; -.
DR   OrthoDB; 1270467at2759; -.
DR   PhylomeDB; Q08050; -.
DR   TreeFam; TF333250; -.
DR   PathwayCommons; Q08050; -.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition.
DR   SIGNOR; Q08050; -.
DR   BioGRID-ORCS; 2305; 183 hits in 1023 CRISPR screens.
DR   ChiTaRS; FOXM1; human.
DR   EvolutionaryTrace; Q08050; -.
DR   GeneWiki; FOXM1; -.
DR   GenomeRNAi; 2305; -.
DR   Pharos; Q08050; Tbio.
DR   PRO; PR:Q08050; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q08050; protein.
DR   Bgee; ENSG00000111206; Expressed in ventricular zone and 137 other tissues.
DR   ExpressionAtlas; Q08050; baseline and differential.
DR   Genevisible; Q08050; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0090344; P:negative regulation of cell aging; IMP:UniProtKB.
DR   GO; GO:0032873; P:negative regulation of stress-activated MAPK cascade; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:2000781; P:positive regulation of double-strand break repair; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0071156; P:regulation of cell cycle arrest; IMP:BHF-UCL.
DR   GO; GO:0001558; P:regulation of cell growth; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0046578; P:regulation of Ras protein signal transduction; IMP:BHF-UCL.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR042839; FOXM1.
DR   InterPro; IPR018122; TF_fork_head_CS_1.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR46878; PTHR46878; 1.
DR   Pfam; PF00250; Forkhead; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00657; FORK_HEAD_1; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Cell cycle; DNA damage;
KW   DNA repair; DNA-binding; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..763
FT                   /note="Forkhead box protein M1"
FT                   /id="PRO_0000091863"
FT   DNA_BIND        235..327
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00089"
FT   COMPBIAS        480..513
FT                   /note="Glu/Pro/Ser/Thr-rich"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         376
FT                   /note="Phosphoserine; by CHEK2"
FT                   /evidence="ECO:0000269|PubMed:17101782"
FT   MOD_RES         522
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         611
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:19160488"
FT   MOD_RES         620
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         627
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         662
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         693
FT                   /note="Phosphoserine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:19160488"
FT   MOD_RES         730
FT                   /note="Phosphoserine; by PLK1"
FT                   /evidence="ECO:0000269|PubMed:19160488,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         739
FT                   /note="Phosphoserine; by PLK1"
FT                   /evidence="ECO:0000269|PubMed:19160488,
FT                   ECO:0007744|PubMed:20068231"
FT   CROSSLNK        163
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        201
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        325
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        356
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        422
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        440
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         326..340
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9032290"
FT                   /id="VSP_001547"
FT   VAR_SEQ         423
FT                   /note="V -> VFGEQVVFGYMSKFFSGDLRDFGTPITSLFNFIFLCLSV (in
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:9032290"
FT                   /id="VSP_001548"
FT   VARIANT         402
FT                   /note="A -> E (in dbSNP:rs28990715)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025239"
FT   VARIANT         450
FT                   /note="F -> L (in dbSNP:rs28919868)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025240"
FT   VARIANT         643
FT                   /note="S -> P (in dbSNP:rs3742076)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT                   /id="VAR_020024"
FT   VARIANT         669
FT                   /note="P -> R (in dbSNP:rs28919869)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025241"
FT   VARIANT         673
FT                   /note="P -> L (in dbSNP:rs28919870)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025242"
FT   MUTAGEN         611
FT                   /note="T->A: Prevents phosphorylation by CDK1 and
FT                   subsequent binding of POLO box domains of PLK1; when
FT                   associated with A-693."
FT                   /evidence="ECO:0000269|PubMed:19160488"
FT   MUTAGEN         693
FT                   /note="S->A: Prevents phosphorylation by CDK1 and
FT                   subsequent binding of POLO box domains of PLK1; when
FT                   associated with A-611."
FT                   /evidence="ECO:0000269|PubMed:19160488"
FT   MUTAGEN         730
FT                   /note="S->A: Prevents phosphorylation by PLK1 and impairs
FT                   transcription activity; when associated with A-739."
FT                   /evidence="ECO:0000269|PubMed:19160488"
FT   MUTAGEN         739
FT                   /note="S->A: Prevents phosphorylation by PLK1 and impairs
FT                   transcription activity; when associated with A-730."
FT                   /evidence="ECO:0000269|PubMed:19160488"
FT   CONFLICT        3
FT                   /note="T -> A (in Ref. 2; AAC63595)"
FT                   /evidence="ECO:0000305"
FT   HELIX           241..250
FT                   /evidence="ECO:0007744|PDB:3G73"
FT   STRAND          255..257
FT                   /evidence="ECO:0007744|PDB:3G73"
FT   HELIX           259..269
FT                   /evidence="ECO:0007744|PDB:3G73"
FT   HELIX           272..275
FT                   /evidence="ECO:0007744|PDB:3G73"
FT   HELIX           281..291
FT                   /evidence="ECO:0007744|PDB:3G73"
FT   STRAND          295..299
FT                   /evidence="ECO:0007744|PDB:3G73"
FT   STRAND          306..310
FT                   /evidence="ECO:0007744|PDB:3G73"
FT   TURN            312..314
FT                   /evidence="ECO:0007744|PDB:3G73"
SQ   SEQUENCE   763 AA;  84283 MW;  963CAC8FE7498E9B CRC64;
     MKTSPRRPLI LKRRRLPLPV QNAPSETSEE EPKRSPAQQE SNQAEASKEV AESNSCKFPA
     GIKIINHPTM PNTQVVAIPN NANIHSIITA LTAKGKESGS SGPNKFILIS CGGAPTQPPG
     LRPQTQTSYD AKRTEVTLET LGPKPAARDV NLPRPPGALC EQKRETCADG EAAGCTINNS
     LSNIQWLRKM SSDGLGSRSI KQEMEEKENC HLEQRQVKVE EPSRPSASWQ NSVSERPPYS
     YMAMIQFAIN STERKRMTLK DIYTWIEDHF PYFKHIAKPG WKNSIRHNLS LHDMFVRETS
     ANGKVSFWTI HPSANRYLTL DQVFKPLDPG SPQLPEHLES QQKRPNPELR RNMTIKTELP
     LGARRKMKPL LPRVSSYLVP IQFPVNQSLV LQPSVKVPLP LAASLMSSEL ARHSKRVRIA
     PKVLLAEEGI APLSSAGPGK EEKLLFGEGF SPLLPVQTIK EEEIQPGEEM PHLARPIKVE
     SPPLEEWPSP APSFKEESSH SWEDSSQSPT PRPKKSYSGL RSPTRCVSEM LVIQHRERRE
     RSRSRRKQHL LPPCVDEPEL LFSEGPSTSR WAAELPFPAD SSDPASQLSY SQEVGGPFKT
     PIKETLPISS TPSKSVLPRT PESWRLTPPA KVGGLDFSPV QTSQGASDPL PDPLGLMDLS
     TTPLQSAPPL ESPQRLLSSE PLDLISVPFG NSSPSDIDVP KPGSPEPQVS GLAANRSLTE
     GLVLDTMNDS LSKILLDISF PGLDEDPLGP DNINWSQFIP ELQ
//
